🇺🇸 ARS Pharmaceuticals, Inc.
Forum topic · SPRY · Company page: financials, ownership and filings
Join the discussion on ARS Pharmaceuticals, Inc.
Loading…
Results announced on 5 November 2026
ARS Pharmaceuticals, Inc. announced results on 5 November 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $38 million (up 16% from a year earlier) and a net loss of $36 million.
Mutual funds: 113 funds hold $160 million
113 mutual funds in 1 country hold shares of ARS Pharmaceuticals, Inc. worth $160 million, about 20.0% of the company (funds' newest reports, up to 31 July 2026).
Since their previous reports 59 funds added shares and 37 sold; on balance they bought $24 million. Share splits are not counted as trading.
Source: Automatic updates: SEC filings, regulators' notices and fund reports held on this site. Posts marked 🤖 are written automatically from official data and state no opinion. Member comments are their authors' views, shown after an editor's review; they are not investment advice.